Clinical trial Recruiting at 9 sites Phase 3 Interventional Ages 18 and up

TSND-201 treatment for PTSD in adults

Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD

Run by Transcend Therapeutics · NCT07836647 · Data updated 2026-11-12

This study tests two doses of TSND-201 or placebo to see if it helps adults with PTSD.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment300 (estimated)
SponsorTranscend Therapeutics
Industry-sponsored
Locations9 sites (Denver, Colorado and 8 other locations)
StatusRecruiting
StartedSeptember 25, 2026
Main results expectedFebruary 2028
Study endsFebruary 2028
Registry record updatedNovember 3, 2026
Trial IDNCT07836647 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with a current PTSD diagnosis of at least 6 months who have tried another pharmacologic treatment or trauma-focused therapy and can participate in study interviews and questionnaires.

Probably not a fit

Participants who do not respond to TSND-201 or those with exclusionary health conditions may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 3 trial enrolls adults with PTSD who have tried other treatments. Participants are randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, administered weekly during a 4-week treatment period, followed by an 8-week follow-up. The study assesses safety and how well TSND-201 works for reducing PTSD symptoms. Key assessments include interviews and questionnaires to monitor response and adverse effects. Locations include sites in Colorado and Florida, sponsored by Transcend Therapeutics.

Why it matters

Potential benefit: If successful, TSND-201 could reduce PTSD symptoms and improve daily functioning for adults with PTSD.

How similar studies have gone: Previous research in related neuroplastogen approaches has shown promise, but this exact TSND-201 strategy is novel in PTSD.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Meets DSM-5 criteria for current PTSD diagnosis, with a symptom duration of at least 6 months.
* Tried at least one pharmacological treatment for PTSD or trauma-focused psychotherapy.
* Proficient in communication (verbal and reading) to complete interviews and written questionnaires.
* Free from any other clinically significant illness or disease.

Exclusion Criteria:

* Primary diagnosis of any other DSM-5 disorder.
* Body mass index (BMI) \<18kg/m2 or ≥40 kg/m2.
* Unable to refrain from nicotine use for at least 8 hours.
* Use of prohibited concomitant medications or therapies.
* Current or previous history of clinically significant cardiovascular (including current uncontrolled hypertension) / cerebrovascular conditions.

Where it's running

  • Mountain View Clinical Research
    Denver, Colorado, United States
    Recruiting
  • Bradenton Research Center
    Bradenton, Florida, United States
    Recruiting
  • CNS Healthcare
    Orlando, Florida, United States
    Recruiting
  • CenExel Tampa
    Tampa, Florida, United States
    Recruiting
  • K2 Medical Research Tampa
    Tampa, Florida, United States
    Recruiting
  • CenExel Atlanta
    Atlanta, Georgia, United States
    Recruiting
Show 3 more locations
  • CenExel Marlton
    Marlton, New Jersey, United States
    Recruiting
  • Bio Behavioral Health
    Toms River, New Jersey, United States
    Recruiting
  • Cedar Clinical Research
    Draper, Utah, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.